vs
Side-by-side financial comparison of First Foundation Inc. (FFWM) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $48.4M, roughly 1.8× First Foundation Inc.). On growth, First Foundation Inc. posted the faster year-over-year revenue change (421.7% vs 17.7%). First Foundation Inc. produced more free cash flow last quarter ($-35.2M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs -2.7%).
John B. Lacson Colleges Foundation (Bacolod), Inc. is a private maritime college in Bacolod, Negros Occidental, Philippines.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
FFWM vs IOVA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $48.4M | $86.8M |
| Net Profit | $-8.0M | — |
| Gross Margin | — | 67.4% |
| Operating Margin | -97.5% | -84.7% |
| Net Margin | -97.9% | — |
| Revenue YoY | 421.7% | 17.7% |
| Net Profit YoY | 43.0% | — |
| EPS (diluted) | $-0.09 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $48.4M | $86.8M | ||
| Q3 25 | $63.6M | $67.5M | ||
| Q2 25 | $51.4M | $60.0M | ||
| Q1 25 | $71.4M | $49.3M | ||
| Q4 24 | $9.3M | $73.7M | ||
| Q3 24 | $9.2M | $58.6M | ||
| Q2 24 | $57.5M | $31.1M | ||
| Q1 24 | $51.1M | $715.0K |
| Q4 25 | $-8.0M | — | ||
| Q3 25 | $-146.3M | $-91.3M | ||
| Q2 25 | $-7.7M | $-111.7M | ||
| Q1 25 | $6.9M | $-116.2M | ||
| Q4 24 | $-14.1M | — | ||
| Q3 24 | $-82.2M | $-83.5M | ||
| Q2 24 | $3.1M | $-97.1M | ||
| Q1 24 | $793.0K | $-113.0M |
| Q4 25 | — | 67.4% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 5.5% | ||
| Q1 25 | — | -0.8% | ||
| Q4 24 | — | 68.7% | ||
| Q3 24 | — | 46.2% | ||
| Q2 24 | — | -0.8% | ||
| Q1 24 | — | — |
| Q4 25 | -97.5% | -84.7% | ||
| Q3 25 | -92.7% | -140.7% | ||
| Q2 25 | -21.1% | -189.8% | ||
| Q1 25 | 8.8% | -245.8% | ||
| Q4 24 | -247.7% | -117.5% | ||
| Q3 24 | -1276.7% | -152.1% | ||
| Q2 24 | 4.6% | -327.6% | ||
| Q1 24 | -0.2% | -16464.6% |
| Q4 25 | -97.9% | — | ||
| Q3 25 | -230.1% | -135.3% | ||
| Q2 25 | -15.0% | -186.2% | ||
| Q1 25 | 9.7% | -235.5% | ||
| Q4 24 | -152.2% | — | ||
| Q3 24 | -896.9% | -142.7% | ||
| Q2 24 | 5.4% | -312.2% | ||
| Q1 24 | 1.6% | -15800.8% |
| Q4 25 | $-0.09 | — | ||
| Q3 25 | $-1.78 | — | ||
| Q2 25 | $-0.09 | $-0.33 | ||
| Q1 25 | $0.08 | $-0.36 | ||
| Q4 24 | $-0.24 | $-0.24 | ||
| Q3 24 | $-1.23 | $-0.28 | ||
| Q2 24 | $0.05 | $-0.34 | ||
| Q1 24 | $0.01 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.6B | $297.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $912.6M | $698.6M |
| Total Assets | $11.9B | $913.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.6B | $297.0M | ||
| Q3 25 | $1.7B | $300.8M | ||
| Q2 25 | $1.1B | $301.2M | ||
| Q1 25 | $1.0B | $359.7M | ||
| Q4 24 | $1.0B | $323.8M | ||
| Q3 24 | $1.1B | $397.5M | ||
| Q2 24 | $1.4B | $412.5M | ||
| Q1 24 | $1.6B | $356.2M |
| Q4 25 | $912.6M | $698.6M | ||
| Q3 25 | $917.9M | $702.3M | ||
| Q2 25 | $1.1B | $698.5M | ||
| Q1 25 | $1.1B | $767.9M | ||
| Q4 24 | $1.1B | $710.4M | ||
| Q3 24 | $1.1B | $773.5M | ||
| Q2 24 | $933.2M | $768.5M | ||
| Q1 24 | $928.7M | $680.0M |
| Q4 25 | $11.9B | $913.2M | ||
| Q3 25 | $11.9B | $904.9M | ||
| Q2 25 | $11.6B | $907.4M | ||
| Q1 25 | $12.6B | $966.7M | ||
| Q4 24 | $12.6B | $910.4M | ||
| Q3 24 | $13.4B | $991.1M | ||
| Q2 24 | $13.7B | $964.3M | ||
| Q1 24 | $13.6B | $869.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-31.9M | $-52.6M |
| Free Cash FlowOCF − Capex | $-35.2M | $-61.9M |
| FCF MarginFCF / Revenue | -72.8% | -71.3% |
| Capex IntensityCapex / Revenue | 6.9% | 10.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-45.9M | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-31.9M | $-52.6M | ||
| Q3 25 | $9.2M | $-78.7M | ||
| Q2 25 | $-16.3M | $-67.4M | ||
| Q1 25 | $-552.0K | $-103.7M | ||
| Q4 24 | $-8.7M | $-73.3M | ||
| Q3 24 | $14.2M | $-59.0M | ||
| Q2 24 | $-9.1M | $-98.4M | ||
| Q1 24 | $7.2M | $-122.3M |
| Q4 25 | $-35.2M | $-61.9M | ||
| Q3 25 | $8.6M | $-89.5M | ||
| Q2 25 | $-16.7M | $-74.9M | ||
| Q1 25 | $-2.5M | $-109.9M | ||
| Q4 24 | $-11.4M | $-77.5M | ||
| Q3 24 | $13.4M | $-61.3M | ||
| Q2 24 | $-9.4M | $-98.9M | ||
| Q1 24 | $5.9M | $-126.5M |
| Q4 25 | -72.8% | -71.3% | ||
| Q3 25 | 13.5% | -132.7% | ||
| Q2 25 | -32.4% | -124.9% | ||
| Q1 25 | -3.5% | -222.8% | ||
| Q4 24 | -123.5% | -105.1% | ||
| Q3 24 | 146.2% | -104.6% | ||
| Q2 24 | -16.3% | -317.9% | ||
| Q1 24 | 11.6% | -17685.3% |
| Q4 25 | 6.9% | 10.7% | ||
| Q3 25 | 1.0% | 16.1% | ||
| Q2 25 | 0.8% | 12.4% | ||
| Q1 25 | 2.8% | 12.6% | ||
| Q4 24 | 29.4% | 5.7% | ||
| Q3 24 | 9.0% | 3.9% | ||
| Q2 24 | 0.4% | 1.4% | ||
| Q1 24 | 2.5% | 583.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.08× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -2.96× | — | ||
| Q1 24 | 9.09× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FFWM
Segment breakdown not available.
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
